Immunocore (IMCR) Q2 Revenue Jumps 30%

Immunocore Plc (NASDAQ:IMCR), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increase, with $98.0 million (GAAP) surpassing consensus estimates of $92.15 million. However, earnings per share (GAAP) landed at $(0.20), below the analyst forecast of $(0.13), as operational costs rose. The quarter showcased robust sales expansion for KIMMTRAK, with net product sales (GAAP) of $98.0 million, representing a 30% year-over-year increase and an improving net loss (GAAP), but higher investments in development led to an earnings miss compared to expectations. Source: Analyst estimates for the quarter provided by FactSet. Immunocore is a U.K.-based biotech that develops and commercializes T cell receptor (TCR) therapies, which are medicines that use engineered T cells to target and kill cancer cells or treat diseases. Its leading asset is KIMMTRAK, a treatment for unresectable or metastatic uveal melanoma, approved in dozens of countries.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool